Cytokinetics Inc
CYTK
Market Cap$3.79B
Close$
$-11.36
137.1% downside
Current Fair Value
137.1% downsideOvervalued by 137.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.79 Billion |
|---|---|
| Enterprise Value | $4.53 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.26 |
| Beta | 0.81 |
| Outstanding Shares | 118,075,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.35 |
|---|---|
| PEG | -26.4 |
| Price to Sales | - |
| Price to Book Ratio | -15.31 |
| Enterprise Value to Revenue | 1407.71 |
| Enterprise Value to EBIT | -8.64 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | -6.21 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cytokinetics Inc
CEO: Robert Blum